@dj_papz Profile picture

Mike

@dj_papz

When nothing goes right, go left.

Joined January 2013
Similar User
Col2014@newusername photo

@newusername2014

Simon Hills 😊 photo

@Simon030374

Leonard Womble photo

@ShareWomble

Ed McDermott photo

@edmcdermott12

Karl2991 photo

@KarlCampbell6

1971bod photo

@1971bod

G photo

@c_brown88

MikeMcMadd photo

@MikeMcMadd

Cabs84 photo

@The_battmobile

Dazler photo

@60Toad60

🄽🄰🄸🄼 photo

@NameOfTheAim

The Dude photo

@ElDuderino00

DU photo

@greenhamneggs

Markieuk photo

@Runnamark

Wolf Of Wallsend photo

@Seanhog1

Mike Reposted

#SEED Church Mouse does a fantastic job extracting the information in an ultra long format interview with CEO Ed McDermott. It was a very impressive performance by Ed. Well done 👏 m.youtube.com/watch?v=HrF-us…


Mike Reposted

$PRTG SITC (Nov 23) data being presented on their lead two drugs -both solely owned Funding cleared up , data coming , clear upward trajectory on stock trading well below NAP

Tweet Image 1
Tweet Image 2

Mike Reposted

🔍 With £7.1 million in cash and receivables, SEED is well-positioned to capitalise on future investment opportunities in the health, wellness, and biotech sectors.  shorturl.at/etuv2 #InvestmentOpportunities #SEED


Mike Reposted

£7.1m of cash and receivables represent circa 3.3p which includes zero value for the investee companies. To name a few of our investments and the current holding values: Juv - £2.56m Avextra - £1.9m Clean Food Group - £965k #SEEDinnov #Seed

🔍 With £7.1 million in cash and receivables, SEED is well-positioned to capitalise on future investment opportunities in the health, wellness, and biotech sectors.  shorturl.at/etuv2 #InvestmentOpportunities #SEED



Mike Reposted

Check the BID out on #SEED DYOR. Cash cow galore this. Share buy-back flagged PLUS you know no dirty placing round the corner!! Stick my neck out with a 9p p/t working all the numbers/cash/assets out. #WhatsNotToLike

Tweet Image 1

Mike Reposted

#SEED sat way below cash/assets £10m NAV with plenty of news ahead Talk of possible share buy back scheme as per AGM +10% on small volume


Mike Reposted

$PRTG collaboration with #merck announced on PORT6 and PORT7 with #keytruda ir.portagebiotech.com/news-releases/…


Mike Reposted

$PRTG strong news from my biggest LTH. 2nd collab with Merck in 16 months Trading below NAV and huge upside potential. Solid results seen following asco , CR in a number of patients. One stock to keep dialed into. Next horizon/biohaven in the making

Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors - Health Stocks Hub $PRTG healthstockshub.com/news/nasdaq/pr…



Mike Reposted

Shares of #SEED have finally started to turn around in recent weeks, finding good support above 2p, and chart-wise looking to head to 3p over the coming weeks. The arrival of Mr Pascual, apparently something of a high flyer (Level III, CFA), could help this recovery along.…

@ZaksTradersCafe Comment on this morning's early"RNS Hotlist" Friday 1st September 2023... Zak's Pre-Market Announcement highlights #TLY, #SLE, #AAA, #EDL, #SKA, #SEED, #TRR, #VDTK, #IRON, #KIBO & #MAST share-talk.com/rns-hotlist-wi…



Mike Reposted

#SEED- Breaking out of the wedge pattern today. Been consolidating primed for a move Think we get 3p pretty quickly and then the share buy backs start in early Sept its going to go mental with the lack of freefloat I'm holding for that 4.5p-5p area Ultimately i could easily…

Tweet Image 1

Mike Reposted

#SEED trading at 25% of NAV MCAP covered by cash and liquid assets £2.5m cash incoming April 24 Plenty of upcoming news for their unlisted assets to sky the NAV

Tweet Image 1

$PRTG Portage Biotech announce dosing of the 1st patient in a Phase 1a trial, evaluating their adenosine 2A receptor inhibitor in select solid tumors. #adenosine 🎯

We’re excited to announce that we have dosed the first patient in our Phase 1a trial evaluating our adenosine 2A receptor inhibitor in select solid tumors. We look forward to exploring our next-gen approach to target the #adenosine pathway. Learn more: fal.cn/3zoW9

Tweet Image 1


$PRTG Portage Biotech #iNKT 🎯

While at #ASCO23, our CEO Dr. Ian Walters spoke with @OncologyTube about Portage’s updated data on its #iNKT engager for the treatment of #melanoma and #NSCLC. Learn more about the #clinicaltrial results here: fal.cn/3zhvu



Mike Reposted

#SEED #SEEDINNOV Brief History March 2017-March 18 NAV moved from £10m to £13m and the SP hit 29p Current NAV ~£17m Current SP 2p Near term IPOs etc upcoming Nothing is as fickle as market sentiment.


Mike Reposted

Thanks @dj_papz for the chart This representation dramatically shows the extent of discount now on offer with #SEED #seedinnov Sitting with £3m cash and a 78% SP discount to NAV it needs to rise by a massive ~450% to catch up

Tweet Image 1

Mike Reposted

#SEEDinnov is trading at circa £3.85m mkt cap (1.8p) with cash at hand of £2.5m plus receivables of £2.5m in April 2024. Our last recorded NAV at September 2022 recorded a 7.84p or £16.689m valuation.


Mike Reposted

$PRTG @PortageBiotech some very good news coming out today at #ASCO2023. #iNkt “Several target lesions were substantially reduced in size or completely resolved, and a majority of target lesions being clinically stable after twelve weeks,” said Dr. Ian Walters.

We’re pleased to share updated interim data on our lead #iNKT engager in a Phase 1/2 study for the treatment of #melanoma and #NSCLC at #ASCO23. For more details on the poster, click here: bit.ly/3qogjN0

Tweet Image 1


Mike Reposted

$PRTG huge PR coming in the next week or so on early efficacy seen in their lead #inkt asset imm60. NSCLC 100% patients prior pd-1 No grade 3-5 19 lesions (2CR /10 SD /1 MR /6 PR All at low/ mid dose range Results be it early are up there with KEYTRUDA! $21bn pa drug! #ASCO23


Mike Reposted

$PRTG. It’s a big deal!!

$PRTG “well tolerated” “no MTD was determined” “2 lesions completely resolved” we can’t forget these patients have sadly been through several other treatments that failed. Well done @PortageBiotech you seem to be improving outcomes with PORT2 🙏 #ASCO23 #CancerResearch

Tweet Image 1


Mike Reposted

$PRTG. We’ve waited a few years for confirmation. I like what I am reading.

$prtg CR in target lesions without establishing MTD. Patients have failed all other treatments so quite incredible early results seen #ASCO23

Tweet Image 1


Loading...

Something went wrong.


Something went wrong.